Adults aged 18-70 with hidradenitis suppurativa (HS) for at least 1 year,may qualify to partcipate. Individuals must have HS lesions present in at least 2 distinct body areas, and a total abscess and inflammatory nodule (AN) count of 5 or more. In addition, qualified participants must not have a history of active skin disease other than HS that could interfere with the assessment of HS.
NCT05216224
Aclaris Therapeutics, Inc.
Brief Summary:
Aclaris Therapeutics, Inc.
Condition or Disease:
Hidradenitis Suppurativa
Intervention/Treatment:
Drug: ATI-450 Drug: Placebo oral tabletPhase:
Phase 2
Ages Eligible for Study:
18 Years and 70 Years (Adult,Older Adult)
Sexes Eligible for Study:
All
Inclusion Criteria:
Able to comprehend and be willing to sign the Institutional Review. Board (IRB)-approved patient prior to administration of any study-related procedures.
Patient must have stable HS.
Total abscesses and/or nodule (AN) count of ≥5 at Baseline visit.
HS lesions present in at least 2 distinct anatomical areas at Screening and Baseline.
Exclusion Criteria:
Patient has a history of active skin disease other than HS that could interfere with the assessment of HS.
Patient has an uncontrolled non-immunoinflammatory disease that may place the patient at increased risk during the study or impact the interpretation of results, e.g., previous malignancy, previous venous thromboembolism.
Patient has experience with >2 biologics, >1 Janus kinase (JAK) inhibitor, or a combination of 1 biologic experience and 1 JAK inhibitor.
Are currently receiving corticosteroids at doses greater than 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of the Screening visit.
Mason - Dermatologists of Southwest Ohio
Similar Trials
No Similar Trials Found
register now
REGISTER NOW